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Background: 3,3′-diindolylmethane (DIM) is an acid-catalyzed dimer of idole-3-carbinol (I3C), a phytochemical
found in cruciferous vegetables that include broccoli, Brussels sprouts and cabbage. DIM is an aryl hydrocarbon
receptor (AhR) ligand and a potential anticancer agent, namely for the treatment of breast cancer. It is also
advertised as a compound that regulates sex hormone homeostasis.
Methods: Here we make use of RNA expression assays coupled to Chromatin Immunoprecipitation (ChIP) in breast
cancer cell lines to study the effect of DIM on estrogen signaling. We further make use of growth assays, as well as
fluorescence-activated cell sorting (FACS) assays, to monitor cell growth.
Results: In this study, we report that ‘physiologically obtainable’ concentrations of DIM (10 μM) activate the
estrogen receptor α (ERα) signaling pathway in the human breast cancer cell lines MCF7 and T47D, in a 17β-
estradiol (E2)-independent manner. Accordingly, we observe induction of ERα target genes such as GREB1 and TFF1,
and an increase in cellular proliferation after treatment with 10 μM DIM in the absence of E2. By using an ERα
specific inhibitor (ICI 182 780), we confirm that the transcriptional and proliferative effects of DIM treatment are
mediated by ERα. We further show that the protein kinase A signaling pathway participates in DIM-mediated
activation of ERα. In contrast, higher concentrations of DIM (e.g. 50 μM) have an opposite and expected effect on
cells, which is to inhibit proliferation.
Conclusions: We document an unexpected effect of DIM on cell proliferation, which is to stimulate growth by
inducing the ERα signaling pathway. Importantly, this proliferative effect of DIM happens with potentially
physiological concentrations that can be provided by the diet or by taking caplet supplements.Background
Breast cancer is one of the leading causes of death in in-
dustrialized countries and estrogens are known to play a
role in its promotion [1]. Initiation of breast cancer by
17β-estradiol (E2) can involve the formation of DNA dam-
age via its oxidation products. Accordingly, E2 is a sub-
strate for the phase I cytochrome P450 (CYP) enzymes,
CYP1A1 and CYP1B1. These two enzymes oxidize E2 into
2-hydroxyestradiol (2-OHE2) and 4-hydroxyestradiol (4-
OHE2), respectively [2,3]. The 2-OHE2 metabolites can
bind estrogen receptor α (ERα), but do not induce tran-
scriptional activity [4]. On the other hand, 4-OHE2 hy-
droxylation results in the formation of a carcinogenic* Correspondence: Luc.Gaudreau@USherbrooke.ca
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unless otherwise stated.metabolite that can be further oxidized to highly reactive
semiquinones and quinines [5]. These C-4 metabolites are
well characterized and known to produce DNA adducts
that lead to depurination of DNA [6-9]. CYP1B1 has been
found in high concentrations in many types of tumors
compared to normal tissues [10]. These observations sug-
gest a function for CYP1B1 in promoting tumor growth.
To support this hypothesis, the expression of CYP1B1 has
been observed in mammary tissue many weeks prior to
the appearance of tumors in DMBA-treated rats [11]. Fur-
thermore, in normal mammary tissue, 2-OHE2-derived
metabolites are the main conversion products of E2, while
a significant increase of 4-OHE2-derived metabolites is
observed in cancerous mammary tissue. Based on these
observations, a model has been put forth wherein thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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intracellular level of genotoxic estrogen metabolites [12].
The CYP1A1 and CYP1B1 genes are expressed primarily
in extra-hepatic tissue and are regulated by the aryl hydro-
carbon receptor (AhR), a ligand-activated transcription
factor that belongs to the bHLH/PAS family. AhR ligands
are numerous and belong to several classes of chemicals
including halogenated aromatic hydrocarbons (HAH)
such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), poly-
cyclic aromatic hydrocarbons (PAH) such as benzopyrene,
and phytochemicals found in cruciferous vegetables like
3,3′-diindolylmethane (DIM). Female rodents exposed to
TCDD for two years showed an increase in liver cancer in-
cidence but a decrease in spontaneous mammary tumor
formation [13]. Later studies revealed that TCDD and
other AhR ligands inhibit cellular proliferation of human
breast cancer cell lines, [14,15] as well as DMBA-induced
mammary tumors in rats [16], and, consequently, these
observations highlight a possible functional crosstalk be-
tween AhR and ERα signaling. The potential role of the
AhR signaling pathway in mammary carcinogenesis inhib-
ition led to the development of selective AhR modulators
(SAhRMs) that act as potential anticancer agents. Even if
TCDD possesses chemopreventive and chemotherapeutic
proprieties in breast cancer development, it also induces
acute liver toxicity. SAhRMs, like DIM, are reported to
have the same inhibitory effects on mammary tumor for-
mation in rats without having the deleterious effects of
TCDD and other toxic AhR ligands. DIM is an acid-
catalyzed dimer of indol-3-carbonyl (I3C), a compound
found in cruciferous vegetables such as broccoli, Brussels
sprouts and cabbage. DIM is one of the most biologically
active products examined so far [17], and because of its
potential chemotherapeutic functions, it has been exten-
sively studied. Reports showed that DIM treatment in-
duces a G1 arrest in the cell cycle of breast, ovarian,
prostate, and colon cancer cell lines [18-23]. In addition,
DIM also induces apoptosis and p21 expression in a p53-
independent manner [24-26], and is a low affinity ligand
for AhR. However, conflicting reports can be found in the
literature as to whether DIM is an agonist or an antagonist
of AhR in the expression of the CYP1 family of genes
[27-31]. Furthermore, DIM activates ERα in a ligand-
independent manner, which involves the protein kinase A
(PKA) and mitogen-activated protein kinase (MAPK) sig-
naling pathways under certain conditions [32].
As a natural compound, DIM can easily be taken as a
dietary supplement. However, information regarding
heavy DIM supplementation is scarce, and whether or
not DIM use is safe on a long-term basis is not known.
In this study, we compare the effects of two concentra-
tions of DIM on the expression of AhR and ERα target
genes, as well as test their impact on AhR-ERα crosstalk.
We chose a lower concentration of DIM (10 μM;thereafter the ‘low concentration’), which can theoretically
be reached in the human body by a ‘heavy eater’ of crucif-
erous vegetables, and a higher concentration (50 μM;
thereafter the ‘high concentration’), which is known to
possess strong anti-proliferative effects in cancer cells.
Our results indicate an opposite dose-dependent effect of
DIM in MCF7 and T47D cells in the absence of E2. At the
high concentration, DIM inhibits cell proliferation and in-
duces both p21 and CYP1A1 gene expression. At the low
concentration, in the absence of E2, DIM acts as an estro-
gen mimetic and induces ERα target gene expression and
concomitant cellular proliferation. Moreover, we find that
the estrogenic effects observed following DIM treatment
are mediated by ERα and the PKA signaling pathway.
Methods
Chemicals and reagents
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) was obtained
from Cerilliant Cambridge isotope Laboratories (catalogue
#ED-901-C). 17β-Estradiol (E2) and ICI 182,780 (ICI) were
purchased from Sigma-Aldrich. 3,3′-diindolylmethane
(DIM) was purchased from LKT Laboratories, Inc. (cata-
logue #D3232), and H89 was purchased from Cayman
chemical (catalogue #10010556).
Cell culture and treatments
MCF7, T47D, and MDAMB-231 cell lines from Ameri-
can Type Culture Collection were maintained in DMEM
(Wisent) containing 10% fetal bovine serum (FBS) and
antibiotics. For all the experiments, cells were grown in
phenol red free DMEM medium (Wisent) containing 5%
dextran-coated charcoal-treated FBS and antibiotics for
three days and then treated with different combinations
of chemicals. For expression assays, we treated the cells
for 24 h with 10 nM TCDD, 10 μM or 50 μM DIM, 100
nM E2. For ChIP assays, we treated cells with the same
concentrations as described for the expression assays,
but for 90 min with TCDD and TCDD + E2, and for
60 min with DIM and DIM + E2. In experiments with
ICI H89, and PD98059, we added these chemicals 24 h
prior to other treatments.
RNA isolation and reverse transcription PCR
Cells were seeded in 6-well plates at a density of 0.35 ×
106 cells per well. The day after, the cells were washed
twice with PBS and put in estrogen-free media for 3 days.
The cells were incubated with ligands for 24 h. Total
RNA was extracted from cells using Genelute (Sigma).
cDNA was synthesized from 600 ng of total RNA using
MMLV-RT (Promega).
Quantitative real-time PCR
The synthesized cDNA was diluted to 1:8 and 5 μl of the
dilution was used per reaction. Quantitative real-time
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Green, 2 mM MgCl2, and homemade Taq polymerase. We
used qPCR primers for 36B4 as the internal control during
qPCR. Human CYP1A1, CYP1B1, GREB1, TFF1 and p21
mRNAs were quantified with the following primers: RT
36B4 Fwd-CGACCTGGAAGTCCAACTAC; RT 36B4
Rev-ATCTGCTGCATCTGCTTG; RT CYP1A1 Fwd-TGA
ACCCCAGGGTACAGAGA; RT CYP1A1 Rev-GGCCTCC
ATATAGGGCAGAT; RT CYP1B1 Fwd-AACGTACCGG
CCACTATCAC; RT CYP1B1 Rev-CCACGACCTGATCC
AATTCT; RT GREB1 Fwd-CGTTGGAAATGGAGACA
AGG; RT GREB1 Rev-CTCTGCCTGAAGGATGCTGT;
RT TFF1 Fwd-GTGCAAATAAGGGCTGCTGT; RT TFF1
Rev-GCACATCCCTGCAGAAGTGT; RT p21 Fwd-GGA
GACTCTCAGGGTCGAAA; RT p21 Rev-GGATTAGG
GCTTCCTCTTGG.
ChIP assays
ChIP assays were performed essentially as described previ-
ously [33]. Briefly, cells were crosslinked with 1.1% formal-
dehyde for 10 minutes and then quenched with 125 mM
glycine. Samples were sonicated to generate chromatin
fragments <500 bp. Next, the chromatin was immunopreci-
pitated with specific antibodies against AhR (SantaCruz)
and ERα (SantaCruz). qPCR was performed using a set of
primers relevant to the promoter regions of the CYP1A1.
The primers used in qPCR are ChIP CYP1A1-A Fwd-
CAGCACTAAGGCGATCCTAGA; ChIP CYP1A1-A Rev-
GATTGAAGGATCGGAATGGA. Results are shown as
percent of input.
Cell proliferation assay
Cells were seeded in 48-well plates at a density of 1.5 ×
104 cells per well in estrogen-free media for three days
and then treated with either DMSO; 100 nM E2; 10 μM
DIM; 50 μM DIM; 50 μM ICI; 10 μM H89; 10 μM DIM
and 50 μM ICI; or 10 μM DIM and 10 μM H89. Medium
was replaced every two days. At each time point, cells
were collected, fixed with 4% formaldehyde for 15 min,
and kept in 0.4% formaldehyde/PBS 1X at 4°C until the
last end point was reached. The cells were then washed
once with sterile distilled water and colored with 0.5 mL
of 0.1% crystal violet in 10% ethanol for 20 min. The cells
were washed three times with sterile distilled water and
allowed to air dry. The dye was extracted with 0.5 mL of
10% acetic acid for 20 min. Absorbance was measured at
590 nm in 96-well plates. The values are presented as fold
over day 0. Each treated time-point is the average of nine
wells from three independent experiments and the error
bars represent standard deviation.
FACS
Cells were rinsed with PBS, treated with trypsin and col-
lected. The cells were then fixed in cold 70% ethanol,resuspended in 50 mM sodium citrate HCl pH 7.0, and
treated successively with RNase A and proteinase K. Fi-
nally, the cells were resuspended in Sytox Green (Life
Technologies) dye at a final concentration of 1 μM in
the same buffer. Samples were analysed by flow cytome-
try on a Becton Dickinson FACScalibur cytometer. For
each sample, ten thousand cells were plotted on a histo-
gram with FL-1 on the X-axis and gates were set to dis-
tinguish cells in G1, S, G2/M and sub-G1-phases of the
cell cycle. Data in the figure are expressed as a percent-
age of all gated cells in the sample and represent the
average and standard error of triplicate experiments.
Results
Opposing effects of two AhR agonists on ERα-mediated
repression of CYP1A1 expression
CYP1A1 expression was first measured in MCF7 breast
cancer cells that were grown in estrogen-free medium for
three days and then treated with either 10 nM TCDD or
50 μM DIM, alone, or in combination with 100 nM E2 for
24 h. Co-treatment of cells with E2 and TCDD typically de-
creased CYP1A1 activation by 60% when compared to
TCDD alone (Figure 1A; [33]). Following DIM treatment,
CYP1A1 activity reached levels similar to those found in
TCDD+E2 treated cells. Addition of E2 produced no effect
on DIM-induced CYP1A1 expression (Figure 1A). Similar
results were also obtained in T47D cells, but we observed a
more modest repression effect by E2, as well as weaker acti-
vation of CYP1A1 (see Additional file 1: Figure S1A). We
also monitored CYP1A1 protein levels upon TCDD treat-
ment of cells, and, as expected, the observed effects on
transcription correlated with CYP1A1 protein expression
levels (Additional file 1: Figure S1B). To further investigate
this phenomenon, we sought to verify the recruitment of
AhR and ERα at the CYP1A1 proximal promoter by ChIP
experiments. As expected from the expression results,
co-treatment of cells with TCDD and E2 impairs AhR
binding at the CYP1A1 promoter as compared to TCDD
alone (Figure 1C). For the DIM treated cells, we ob-
served no significant variation of AhR binding when E2
was added (Figure 1C). ERα recruitment to the CYP1A1
promoter is known to occur only when AhR and ERα
signaling pathways are simultaneously activated [34].
Our results are consistent with this, since ERα is
present at the CYP1A1 promoter only after treatment
with TCDD + E2, but not after addition of TCDD alone
(Figure 1D). Treatment of cells with DIM alone, or in
combination with E2, resulted in the recruitment of
both AhR (Figure 1C) and ERα (Figure 1D). This is con-
sistent with the finding that DIM activates both AhR
and ERα signaling pathways [30,35]. Altogether, these
results show that CYP1A1 expression and AhR and ERα
binding at the CYP1A1 promoter are differentially regu-











































































Figure 1 DIM activates both AhR and ER signaling pathways. (A) MCF7 cells, grown in estrogen-free media for three days, then treated with
DMSO, 10nM TCDD, 10nM TCDD + 100nM E2, 50 μM DIM or 50 μM DIM + 100nM E2. After 24 h, the cells were lysed and RNA was extracted and
quantified by RT-qPCR. Results are presented as percent induction over TCDD. (B) Schematic representation of the CYP1A1 promoter and primer
position used for ChIP analysis. ChIPs of AhR (C) and ERα (D) were performed in MCF7 cells, grown in estrogen-free media for three days, then
treated with DMSO, 10nM TCDD, 10nM TCDD + 100nM E2, 50 μM DIM or 50 μM DIM + 100nM E2. Results are showed as% of Input and represent
the mean of three independent experiments with standard deviation.
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to DIM
DIM is documented to be a weak AhR ligand when
compared to TCDD and has been described as an antag-
onist of AhR-mediated gene transcription [30]. Consid-
ering the repressive effect of ERα on AhR signaling, the
activation of ERα by DIM treatment might partly explain
the weaker induction of CYP1A1. This scenario could
also explain why co-treatment of cells with both TCDD
and DIM leads to weaker induction of AhR target genes
in ERα positive cells [30,36]. We next wanted to verify if
depletion of ERα would allow an increase in CYP1A1 ex-
pression after DIM treatment. First, MCF7 cells were
grown in E2-depleted media for three days and then
treated with 50 μM ICI 182 780 (a specific ERα inhibitoralso known as Fulvestran) for 24 h prior to the addition
of 50 μM DIM for another 24 h. We observed a two-
fold increase in CYP1A1 induction in cells treated with
DIM and ICI compared to DIM alone (Figure 2A). A
similar experiment was performed using T47D breast
cancer cells and the results obtained (Additional file 2:
Figure S2) were very comparable to those obtained in
Figure 2A. ChIP experiments performed at the CYP1A1
promoter using AhR and ERα antibodies show that AhR
binding increases when cells are co-treated with DIM
and ICI 182 780 (Figure 2B), and that ICI 182 780 pre-
vents ERα from being recruited to CYP1A1 (Figure 2C).
The latter result is consistent with a previous study that
showed that ICI leads to ERα degradation [37]. Overall,
















































Figure 2 ERα degradation increases CYP1A1 induction in response to DIM. (A) Expression analyses were performed in MCF7 cells grown in
estrogen-free media for three days and treated with 50 μM ICI 182 780 for 24 h prior to the addition of 50 μM DIM for 24 h. ChIPs of AhR (B) and
ERα (C) were performed in MCF7 cells, grown in estrogen-free media for three days and then treated or not with 50 μM ICI 182 780 for 24 h prior
to the addition of 50 μM DIM for 1 h. Results are shown as% of Input and represent the mean of three independent experiments with
standard deviation.
Marques et al. BMC Cancer 2014, 14:524 Page 5 of 10
http://www.biomedcentral.com/1471-2407/14/524CYP1A1 expression. On one hand, DIM binds AhR and
promotes CYP1A1 induction, while on the other, DIM trig-
gers ERα activation and represses CYP1A1 expression.
Different concentrations of DIM preferentially activate
either the AhR or ERα signaling pathways
In the experiments described above, we used 50 μM DIM,
which is considered to be very high (the high concentra-
tion). For instance, Leong and co-workers proposed that a
heavy eater of Brassica vegetables could reach, under
optimal conditions, a DIM blood concentration of ap-
proximately 10 μM [35]. Thus, we decided to compare a
potential physiological concentration of DIM (low concen-
tration = 10 μM) with the high concentration (50 μM). We
treated MCF7 cells grown in estrogen-free media for three
days with the low and the high concentrations of DIM and
then measured the mRNA levels of two AhR target genes
(CYP1A1 and CYP1B1), as well as two ERα target genes
(GREB1 and TFF1). We observed an increase in gene ex-
pression that is directly proportional to DIM concen-
trations for the AhR target genes (Figure 3A and B).
Strikingly, the low concentration of DIM strongly induces
ERα target gene expression, whereas the high concen-
tration has almost no effect on the expression of these
genes (Figure 3C and D). GREB1 protein levels were alsomonitored by immunoblotting using cells treated with
10 μM DIM (Additional file 3: Figure S3A). The results
parallel the mRNA expression levels and show that GREB1
is induced by 10 μM DIM. Taken together, our results sug-
gest that physiological concentrations of DIM stimulate
transcriptional activity of ERα-dependent genes in the ab-
sence of E2 in MCF7 cells. We also repeated these same
experiments in T47D cells and obtained nearly identical
results (Additional file 3: Figure S3B), a result that shows
that these effects are not cell-type specific.
The PKA signaling pathway contributes to DIM-mediated
ligand-independent activation of ERα
A previous study using reporter assays has shown that
the activation of ERα by DIM is independent of its bind-
ing to ERα and involves the PKA signaling pathway and,
to a lesser extent, the MAPK pathway [32]. To test the
role of the PKA signaling pathway in ERα activation by
DIM, we used a specific inhibitor of the PKA pathway,
H89. We measured mRNA levels of CYP1A1, which is
negatively regulated by ERα, and GREB1, which is posi-
tively regulated by ERα. MCF7 cells grown in E2-
depleted media were treated with either 100 nM E2,
10 μM DIM, 10 μM DIM + 50 μM ICI, or 10 μM DIM +































































Figure 3 Effects of different concentrations of DIM on AhR and ERα target gene expression. mRNA levels of AhR target genes CYP1A1 (A)
and CYP1B1 (B) and ERα target genes GREB1 (C) and TFF1 (D) were quantified in MCF7 cells grown in estrogen-free media for three days, then
treated with DMSO, 10 μM DIM or 50 μM DIM for 24 h. Results are shown as fold over DMSO and represent the mean of three independent ex-
periments with standard deviation.
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diated by ERα on CYP1A1 gene expression. Conversely,
we observed that ICI and H89 abolish the induction of
GREB1 by DIM (Figure 4B). As with the previous fig-
ures, we performed the same experiments in T47D
cells and obtained comparable results (Additional file 4:























Figure 4 DIM ligand-independent activation of ERα is mediated by th
level (B) in MCF7 cells grown in estrogen-free media for three days and th
addition of DMSO, 100nM E2, 10 μM DIM, 10 μM DIM + 50 μM ICI or 10 μM
induction and represent the mean of three independent experiments withat least in large part, via the action of the PKA signaling
pathway.
Low concentrations of DIM induce MCF7 proliferation in
the absence of E2
It is known that high concentrations of DIM (>50 μM)























e PKA signaling pathway. CYP1A1 mRNA level (A) and GREB1 mRNA
en treated or not with 50 μM ICI or 10 μM H89 for 24 h prior to the
DIM + 10 μM H89 for 24 h. Results are shown as percent of maximum
standard deviation.
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Moreover, some of these properties have been proposed
to work via induction of the p21 gene, a key regulator of
the cell cycle associated with G1 arrest and senescence
[38]. Conversely, since a low dose of DIM activates ERα,
it might also promote cellular proliferation. We thus de-
cided to compare the effect of both DIM concentrations
on cellular proliferation. We first verified the effect of
high and low-dose DIM treatments on the expression of
p21 by RT-qPCR. We observe that only the high concen-
tration of DIM induces p21 expression in MCF7 cells
(Figure 5A). We then compared MCF7 cell proliferation
using crystal violet staining in E2-depleted media follow-
ing three days of treatment with either E2, 10 μM DIM
or 50 μM DIM (Figure 5B). Strikingly, the two concen-
trations of DIM have opposite effects on cellular prolif-
eration. On the one hand, a low concentration of DIM
stimulates cell growth almost as much as E2 treatment.
On the other hand, a high concentration of DIM inhibits
cell growth (Figure 5B). To verify that the observed ef-
fects of the low concentration of DIM on cellular prolif-
eration were mediated by ERα and the PKA pathway, we
treated MCF7 cells with either ICI or H89, in addition
to DIM (Figures 5C, D). Both the degradation of ERαp21




































0 1 2 3 4
Figure 5 Low concentration of DIM induces MCF7 proliferation in abs
estrogen-free media for three days and then treated with DMSO, 10 μM DI
grown in estrogen-free media and then treated (DMSO, ER, DIM 10 μM or
with 10 μM DIM with or without ICI 182 780. (D) Proliferation assay of MCFand the inhibition of the PKA signaling pathway abro-
gated the proliferative effect of DIM in the absence of
E2. Similar experiments were conducted in T47D cells
with comparable results (Additional file 5).
In order to further confirm the effects of DIM on the
cell cycle, we performed cell cycle assays using flow cytom-
etry (FACS) in T47D cells (Additional file 5: Figure S5B).
The results show that at low concentrations of DIM
(10 μM) the percentage of cells in S-phase is significantly
increased compared to DMSO-treated cells, indicating a
higher proliferation rate similar to cells treated with E2
(Additional file 6). Cells treated with 50 μM DIM tended
to have a lower percentage of S-phase cells than untreated
cells, although the difference was not statistically signifi-
cant (p-value = 0.06). Finally, we performed a FACS experi-
ment under the same conditions but with MDAMB-232
cells, which do not express the ERα. As expected, DIM has
no significant effect (Additional file 6) on cell growth in
this cell line, confirming that the proliferative effect of
DIM is a result of activating the ERα pathway. In conclu-
sion, we observed that treatment with the low concentra-
tion of DIM induced breast cancer cell proliferation in the
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ence of E2. (A) p21 expression was quantified in MCF7 cells grown in
M or 50 μM DIM for 24 h. (B) Proliferation assay of MCF7 cells, first
50 μM) over three days. (C) Proliferation assay of MCF7 cells treated
7 cells treated with 10 μM DIM with or without H89.
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Bidirectional inhibitory crosstalk between AhR and ERα is
very complex and occurs at many regulatory levels [39,40].
AhR ligands have been shown to carry potentially import-
ant chemopreventive properties, thus understanding the
mechanisms behind these properties is fundamental for de-
veloping cancer therapies. DIM has been intensely studied
as a possible therapeutic agent in cancer treatment, espe-
cially for breast cancer. Studies report that DIM treatment
promotes cellular growth arrest of cancer cells, as well as a
decrease in mammary tumor formation in DMBA-treated
rats [16,24,30]. Although the use of DIM as a therapeutic
agent in the treatment of breast cancer is not yet approved,
there are active clinical trials that are testing DIM for the
treatment of many types of cancers (http://clinicaltrials.gov/
ct2/results?term=diindolylmethane). However, DIM can
easily be purchased as a dietary supplement and be self-
administered. As previously mentioned, DIM is a SAhRM
that binds AhR, which is involved in the regulation of the
expression of phase I and II drug metabolizing enzymes.
Discrepancies are found in the literature as to whether
DIM is an agonist or an antagonist of AhR [27-31], thus,
clarification of this issue is important, especially regarding
the potentially toxic effect mediated by AhR agonists in
the liver following AhR activation.
In this study, we tested how the use of different concen-
trations of DIM can lead to opposite biological outcomes.
As previously reported, we confirmed that activation of
ERα by E2 represses the induction of CYP1A1 by approxi-
mately 60% after TCDD treatment. The simultaneous acti-
vation of AhR and ERα when cells are treated with DIM
does not allow full induction of CYP1A1. Furthermore,
addition of E2 to DIM-treated cells has no repressive effect
on CYP1A1 expression, which can be explained by the fact
that ERα is already fully recruited to the CYP1A1 promoter
after DIM treatment alone. We propose that activation of
ERα by DIM can explain, at least in part, some discrepan-
cies found in the literature on the role of DIM as an agon-
ist/antagonist of AhR in ERα positive cell lines [27-31].
DIM concentrations found in the human body are
dependent on the diet. Our first experiments were car-
ried out using a concentration of 50 μM, which is prob-
ably much higher than what can realistically be reached
in the body [35]. We then compared 50 μM DIM with a
more physiological concentration of DIM (10 μM) and
observed that the high concentration of the compound
induces the expression of AhR target genes (CYP1A1
and CYP1B1), while the low concentration shows signi-
ficant effects on the expression of ERα target genes
(GREB1 and TFF1) in the absence of E2. These observa-
tions indicate that at physiological concentrations, DIM
principally mediates estrogenic effects. It can also ex-
plain why oral administration of DIM in rodents has no
hepatic toxicity due to the weak induction of theCYP1A1 gene at this low concentration. ERα activation
can be mediated by direct binding of its main ligand
(E2), but it can also be induced by the activation of the
PKA signaling pathway. The phosphorylation of ERα in-
creases its capacity to interact with the transcription ma-
chinery and triggers the expression of ERα target genes
[41-44]. Accordingly, we were able to demonstrate that
the effect of DIM treatment on CYP1A1 and GREB1 ex-
pression is mediated by ERα, which, in this case, is acti-
vated mostly by the PKA signaling pathway.
Conclusions
The estrogen receptor is highly expressed in almost 70%
of breast cancer cases and its activation promotes cellular
proliferation and tumor development [45]. Our results
demonstrate that DIM, at concentrations likely attainable
by a diet rich in cruciferous vegetables, induces prolifera-
tion of MCF7 and T47D breast cancer cells in the absence
of E2. DIM requires that ERα be activated by the PKA sig-
naling pathway to promote cellular growth in the absence
of E2. Consequently, the abundance of ERα, as well as cir-
culating estrogen levels, will influence the local effects of
DIM on cell growth. Altogether, our findings suggest that
the use of DIM as a dietary supplement or as a therapeutic
agent should be undertaken very cautiously as unexpected
adverse effects could be encountered.
Additional files
Additional file 1: Figure S1. (A) DIM activates both AhR and ER
signaling pathways in T47D cells. Cells were grown in estrogen free
media for 3 days, then treated with DMSO, 10nM TCDD, 10nM TCDD +
100nM E2, 50 μM DIM or 50 μM DIM + 100nM E2. After 24 h, the cells
were lysed, RNA was extracted and reverse transcribed. Results are
presented as percent induction over TCDD. Results represent the mean
of 3 independent experiments with standard deviation. (B) CYP1A1
protein levels are induced by treating cells with 10 μM DIM. Immunoblot
of CYP1A1 using an anti-CYP1A1 antibody in T47D cells. Conditions are
as described in (A) using 10 μM DIM or DMSO-treated cells.
Additional file 2: Figure S2. ERα degradation increases CYP1A1
induction in response to DIM. Expression analysis were performed in T47D
cells grown in estrogen free media for 3 days and treated with 50uM ICI 182
780 for 24 h prior addition of 50uM DIM for 24 h. Results represent the
mean of 3 independent experiments with standard deviation.
Additional file 3: Figure S3. Effects of different concentrations of DIM
on AhR and ERα target gene expressions. Protein levels of GREB1 are
monitored by immunoblotting (A), mRNA levels of AhR target genes
CYP1A1 (B) and CYP1B1 (C) and ERα target genes GREB1 (D) and TFF1
(E) were quantified in T47D cells grown in estrogen free media for
3 days, then treated with DMSO, 10uM DIM or 50uM DIM for 24 h.
Results are showed as fold over DMSO and represent the mean of 3
independent experiments with standard deviation.
Additional file 4: Figure S4. DIM ligand-independent activation of ERα
is not mediated by the PKA signaling pathway in T47D cells. CYP1A1
mRNA level (A) and GREB1 mRNA level (B) in T47D cells grown in
estrogen free media for 3 days, and then treated or not with 50uM ICI or
10uM H89 for 24 h prior addition of DMSO, 100nM E2, 10 μM DIM, 10 μM
DIM + 50 μM ICI or 10 μM DIM + 10 μM H89 for 24 h. Results are showed
as percent of maximum induction and represent the mean of 3 independent
experiments with standard deviation.
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http://www.biomedcentral.com/1471-2407/14/524Additional file 5: Figure S5. Low concentration of DIM induces T47D
proliferation in the absence of E2. (A) p21 expression was quantified in
T47D cells grown in estrogen free media for 3 days and then treated
with DMSO, 10 μM DIM and 50 μM DIM for 24 h. Proliferation of T47D
cells, grown in estrogen free media, was analyzed following various
treatments during 3 days. (B) Comparison of T47D cell proliferation after
DMSO, 100nM E2, 10 μM DIM and 50 μM DIM treatments. (C) Effect of ICI
182 780 on T47D cell proliferation induced by 10 μM DIM treatment.
Additional file 6: Figure S6. FACS analysis of cells treated with either
10 or 50 μM DIM. (A) T47D or (B) MDAMB-231 cells. Bar plot shows the
percentage of S-phase cells in each sample.
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